NCT07677137招募中不适用
A Monocentric, Single-arm, Single-blind Withdrawal First-in-human Study to Assess the Initial Safety, Tolerability, and Effectiveness of the ONSS Bilateral Occipital Nerve Field Stimulation System for the Prophylactic Treatment of Chronic Cluster Headache in Difficult-to-treat Subjects.
Man and Science, SA1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2026年5月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Number of procedure-related or device-related adverse events at 12 weeks
研究概览
简要总结
The purpose of this clinical trial is to evaluate the safety and effectiveness of the Occipital Nerve Stimulation System (ONSS) in treating chronic cluster headache in adults.
The study aims to answer the following questions:
- What adverse events or medical complications occur following ONSS implantation and stimulation?
- Does treatment with the ONSS reduce the frequency of cluster headache attacks compared with baseline?
Participant Involvement
Participants will:
- Undergo implantation of the ONSS device.
- Use the ONSS for a 48-week treatment period.
- Attend scheduled clinic visits for follow-up assessments and device evaluations.
- Maintain a diary documenting cluster headache attacks and use of rescue medications.
- Complete study-related assessments throughout the study period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •ICHD-3 criteria for chronic cluster headache
- •Documented history of CCH since at least 1 year
- •Minimum mean attack frequency of 4 attacks per week at baseline (-4week to +2 week up to implant)
- •Documented minimum 4 weeks of retrospective cluster headache diary data
- •Age range: 22-70 years
- •Difficult-to-treat CCH with documented previous complete failure, insufficient efficacy, intolerance, or contra-indications to most preventive CH treatments among which are oral steroids or suboccipital infiltrations, verapamil, lithium carbonate and topiramate.
- •No preventive CH treatment or stable preventive CH medication for ≥ 2 weeks before enrolment.
- •Subject agrees not to change existing treatment during the whole duration of the trial.
- •Participant written informed consent provided before enrolment
- •Participant willing and capable of subjective evaluation and to fill in an electronic CH diary, to understand questionnaires, and to read, understand and sign the written informed consent form.
- •Partcipant willing and able to comply with study-related requirements, procedures, and visits.
排除标准
- •Other significant neurological, psychiatric, or disabling diseases which in the opinion of the investigator may interfere with the study.
- •History of epilepsy, current treatment of epilepsy
- •Documented history of cerebrovascular accident (CVA)
- •Participants suffering from a substance use disorder, as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria. Recreational use of cannabis is allowed.
- •Participants at high risk of suicide/suicidal ideation in the past one year assessed with the C-SSRS at screening
- •Having another active implanted device such as a cardiac pacemaker, a spinal cord, peripheral nerve, sphenopalatine ganglion, or deep brain hypothalamic stimulator, and/or a drug delivery pump, etc.
- •Cranial botulinum toxin injections in the past 3 months before enrolment. Administration of the following treatments in the last month before enrolment: monoclonal antibodies blocking calcitonin gene-related peptide transmission, suboccipital infiltrations with steroids and/or local anesthetics, oral steroids, radiofrequency procedure or infiltrations of the sphenopalatine ganglion, opioids WHO
- •Oral or systemic steroids are not allowed during the month before enrolment, except low doses (prednisone not superior to 10mg/day for no more than 7 days) if needed for other disorders.
- •Medication overuse headache (ICHD 3 8.2)
- •Inability to fill out an electronic diary.
- •Previous surgery or trauma involving the cervical spine or the occipital bone
- •Coagulopathy or required anticoagulant medications that cannot be safely discontinued in the perioperative period.
- •Concurrent participation in another clinical study
- •Planned pregnancy, pregnancy, or breastfeeding.
结局指标
主要结局
Number of procedure-related or device-related adverse events at 12 weeks
时间窗: From implantation to 12 weeks post implantation
Number of adverse events at 48 weeks
时间窗: From implantation to 48 weeks post-activation
次要结局
- Change in the mean weekly attack frequency(From enrollment to 48 weeks post-activation)
- 50% Responder rate(From enrollment to 48 weeks post-activation)
- 30% Responder rate(From enrollment to 48 weeks post-activation)
- Change in the mean weekly attack intensity compared to baseline(From enrollment to 48 weeks post-activation)
- Change in the mean number of weekly attack treatments compared to baseline(From enrollment to 48 weeks post-activation)
- Scalp distribution of stimulation-induced paraesthesia per scalp region assessed using an 18-region scalp mapping tool(From enrollment to 48 weeks post-activation)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Effectiveness of a Nerve Block in the Back of the Head for Treating Headaches Caused by Bleeding in the BrainSpontaneous subarachnoid hemorrhage2025-520619-15-00Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau40
尚未招募
2 期
A study to see whether an injection near the back of the head (greater occipital nerve block) can help reduce pain and headache days in people with chronic migraineCTRI/2025/10/096122AIIMS Gorakhpur38
进行中（未招募）
不适用
Neural Mobilization vs Cervical Neuromodulation in DPNDiabetic Peripheral Neuropathy Type 2NCT07537270Abeer Abdrabo75
尚未招募
不适用
Comparison Between Greater Occipital Nerve Block and Pulsed Radiofrequency in the Management of Chronic MigraineChronic Migraine, HeadacheNCT07512219Sohag University70
尚未招募
不适用
Immediate effects of a gentle neck muscle release technique alone and combined with a specific neck mobilization technique, on headache intensity, neck-related disability and neck movement in people with cervicogenic headacheCTRI/2026/03/10621550